- Conditions
- Renal Cell Carcinoma
- Interventions
- Lenvatinib, Everolimus, Pembrolizumab, Sunitinib
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,069 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 35
- States / cities
- Stanford, California • Boca Raton, Florida • Fort Myers, Florida + 29 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 438
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Epilepsy
- Interventions
- Not listed
- Lead sponsor
- The Epilepsy Study Consortium
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 6
- States / cities
- Miami, Florida • Chicago, Illinois • Baltimore, Maryland + 2 more
- Conditions
- Breast Cancer
- Interventions
- Eribulin Mesylate
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 26
- States / cities
- Denver, Colorado • Davie, Florida • Jacksonville, Florida + 22 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Interventions
- MRS Spectroscopy
- Other
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Refractory Solid Tumors, Lymphomas
- Interventions
- Lenvatinib, Moxifloxacin 400 mg, Placebos (matched to 4 mg and 10 mg lenvatinib capsules).
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Myeloma, Plasma-Cell, Lymphoma, Malignant
- Interventions
- Palonosetron, Aprepitant, Dexamethasone
- Drug
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Human Papilloma Virus, Recurrent Respiratory Papillomatosis, Pulmonary Disease
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Interventions
- E2814, Lecanemab, Matching Placebo (E2814)
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
- Conditions
- Metastatic Urothelial Cell Cancer
- Interventions
- Eribulin Mesylate, Avelumab
- Drug
- Lead sponsor
- Monika Joshi, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Iowa City, Iowa • Hershey, Pennsylvania
- Conditions
- Glioma
- Interventions
- Lenvatinib, Bevacizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 3
- States / cities
- Tampa, Florida • Boston, Massachusetts • Durham, North Carolina
- Conditions
- Alzheimer's Disease
- Interventions
- Active Comparator: A, Placebo Comparator B, Active Comparator B, Placebo Comparator A
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 8
- States / cities
- Garden Grove, California • San Francisco, California • Orlando, Florida + 5 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
- Interventions
- E7820
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 7
- States / cities
- Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 4 more
- Conditions
- Tumors
- Interventions
- Lenvatinib, Pembrolizumab
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 357 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 50
- States / cities
- Anchorage, Alaska • Oro Valley, Arizona • Tucson, Arizona + 34 more
- Conditions
- Advanced Hepatocellular Carcinoma, Hepatocellular Carcinoma, Liver Cancer, Liver Neoplasms, Hepatic Cancer, Hepatic Carcinoma
- Interventions
- H3B-6527
- Drug
- Lead sponsor
- H3 Biomedicine Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 15
- States / cities
- Los Angeles, California • Newport Beach, California • Orange, California + 11 more
- Conditions
- HER2-positive Breast Cancer, Metastatic Breast Cancer
- Interventions
- Pertuzumab, Trastuzumab, eribulin
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Impotence, Prostate Cancer
- Interventions
- GPI 1485
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 40 Years to 69 Years · Male only
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2003
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • La Mesa, California • Stanford, California + 19 more
- Conditions
- Healthy Subjects
- Interventions
- LEM5, LEM10, ZOL, PBO
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Raleigh, North Carolina + 1 more
- Conditions
- Alzheimer Disease
- Interventions
- Lemborexant 25 mg, Placebo
- Drug
- Lead sponsor
- Brendan Lucey
- Other
- Eligibility
- 60 Years to 80 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Healthy Participants
- Interventions
- E6742, Placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- Lenvatinib, Pembrolizumab, Placebo
- Drug · Biological
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 511 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 26
- States / cities
- Fresno, California • San Marcos, California • Aurora, Colorado + 22 more
- Conditions
- Myelodysplastic Syndrome
- Interventions
- Subcutaneous Decitabine
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 3
- States / cities
- Tucson, Arizona • Tampa, Florida • The Bronx, New York
- Conditions
- Multiple Myeloma
- Interventions
- Palonosetron
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 10
- States / cities
- Beech Grove, Indiana • New York, New York • Winston-Salem, North Carolina + 6 more
- Conditions
- Breast Cancer
- Interventions
- E7389, Physician's Choice
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 762 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Bellflower, California • Gilroy, California + 29 more
- Conditions
- Alzheimer's Disease
- Interventions
- E2212, placebo
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas